Post-marketing Surveillance Study of Adalimumab (Humira®) for Non-infectious Intermediate, Posterior, or Panuveitis Patients
NCT03339102 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 158
Last updated 2021-07-19
Summary
The objective of this study is to evaluate the safety and effectiveness of Humira® (Adalimumab) for the treatment of non-infectious intermediate, posterior, or panuveitis patients under a routine treatment practice.
Conditions
- Non-infectious Intermediate, Posterior and Panuveitis
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
AbbVie Inc. · AbbVie
Eligibility
- Min Age
- 19 Years
- Max Age
- 99 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2018-01-25
- Primary Completion
- 2020-07-16
- Completion
- 2020-07-16
Countries
- South Korea
Study Locations
More Related Trials
-
Multi-country Post-Marketing Observational Study on Maintenance of Effectiveness of Adalimumab (Humira®) in Patients With Ankylosing Spondylitis and Psoriatic Arthritis
NCT01474876 ·Status: COMPLETED
-
Study Of PF-06410293 And Adalimumab In Healthy Subjects (REFLECTIONS B538-01)
NCT01870986 ·Status: COMPLETED ·Phase: PHASE1
-
Effectiveness and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
NCT01078090 ·Status: COMPLETED
-
Special Investigation of Humira® (Adalimumab) on Long-term Treatment in Patients With Rheumatoid Arthritis
NCT01163318 ·Status: COMPLETED
-
Drug Use Investigation for Humira® - All Patient Investigation for Rheumatoid Arthritis
NCT01076959 ·Status: COMPLETED
-
Safety and Effectiveness of Adalimumab in Patients Diagnosed With Rheumatoid Arthritis
NCT01078571 ·Status: COMPLETED
-
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
NCT01077258 ·Status: COMPLETED
-
A Study Of PF-06410293 (Adalimumab-Pfizer) And Adalimumab (Humira) In Healthy Subjects (REFLECTIONS B538-07))
NCT02237729 ·Status: COMPLETED ·Phase: PHASE1
-
Study of the Human Anti-TNF Monoclonal Antibody in Patients With Active Rheumatoid Arthritis
NCT00649545 ·Status: APPROVED_FOR_MARKETING
-
A 3-year Study Following up Patients With Moderate to Severe Rheumatoid Arthritis Treated With Humira in Greece
NCT01086033 ·Status: COMPLETED
-
Serum Concentration of Adalimumab as a Predictive Factor of Clinical Outcomes in Rheumatoid Arthritis (AFORA)
NCT01382160 ·Status: COMPLETED ·Phase: PHASE4
-
Safety and Effectiveness and Effect on Quality of Life and Work Productivity of Humira in Patients With Psoriatic Arthritis in Clinical Routine
NCT01078610 ·Status: WITHDRAWN
-
To Compare the Pharmacokinetics and Safety of CT-P17 and Humira in Healthy Subjects
NCT03970824 ·Status: COMPLETED ·Phase: PHASE1
-
Efficacy of HUMIRA in Subjects With Active Rheumatoid Arthritis
NCT00234897 ·Status: COMPLETED ·Phase: PHASE4
-
Study of Human Anti-TNF Monoclonal Antibody D2E7 in Subjects With Active Rheumatoid Arthritis
NCT00049751 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Assess Change in Disease Activity and Adverse Events of Adalimumab in Chinese Participants Requiring High Dose Corticosteroids for Active Non-Infectious Intermediate, Posterior, or Pan-Uveitis
NCT05414201 ·Status: COMPLETED ·Phase: PHASE4
-
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
NCT01329380 ·Status: COMPLETED
-
A Crossover Study of the Safety and Tolerability of Two Formulations of Adalimumab
NCT01502423 ·Status: COMPLETED ·Phase: PHASE2
-
Comparison of Adalimumab and Infliximab Treatment of Rheumatoid Arthritis
NCT00216177 ·Status: UNKNOWN ·Phase: PHASE4
-
Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)
NCT01346488 ·Status: COMPLETED
-
Efficacy and Safety of Adalimumab in Subjects With Inactive Uveitis
NCT01124838 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety Study of ABP 501 Compared to Adalimumab in Subjects With Moderate to Severe Rheumatoid Arthritis
NCT01970475 ·Status: COMPLETED ·Phase: PHASE3
-
Optimization of Treatment With Adalimumab (Humira)
NCT01585064 ·Status: COMPLETED
-
A Study Of PF-06410293 (Adalimumab-Pfizer) And Adalimumab (Humira®) In Combination With Methotrexate In Subjects With Active Rheumatoid Arthritis (REFLECTIONS B538-02).
NCT02480153 ·Status: COMPLETED ·Phase: PHASE3
-
Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severely Active Psoriatic Arthritis Subjects With Inadequate Response to Disease Modifying Anti-Rheumatic Drug Therapy
NCT00646178 ·Status: COMPLETED ·Phase: PHASE3